Clinical Trial Update: A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 sub-study update for the BMS-986036 program in non-alcoholic steatohepatitis (NASH) with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• BMS-986036

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Alcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2020-02-19